InvestorsHub Logo
Followers 2
Posts 1472
Boards Moderated 0
Alias Born 07/20/2016

Re: None

Wednesday, 05/09/2018 10:23:16 AM

Wednesday, May 09, 2018 10:23:16 AM

Post# of 108192
For the naysayers who have brought up NEO's delay, they are in fact correct. The trial has been delayed. There were changes made for the better, per IR, with which Amgen agreed. Obviously, if Amgen is providing funding, their agreement would be crucial. The hiring of a bioinformatics scientist would clearly indicate the trial is moving forward.

"Contribute to the development of novel approaches for the identification of neoantigens and tumor escape mechanisms." I'm hoping this motivates the best minds to rise to the challenge and apply for the position.

Combo prostate data on the way soon, also. I think a lot is riding on this as CI's have shown little effectiveness for this type of cancer. If the data shows at least some synergy, we could well be on our way out of single digits. No, I don't mean overnight but I believe it would start an upward trajectory. No one investing in this company wants it to fail unless they want to commit financial suicide. Those of us who have been here for a long time are hoping Ken is able to negotiate a deal with cash upfront and NOT with dilution. I think we're approaching some major events and we'll know soon enough if they are positive or negative. I'm still leaning more to positive. I completely understand the frustration, bitterness and outright hate some have for the stock. I'm hoping this year that finally turns into satisfaction and relief for all of us who have waited this long as well as for cancer patients who may well nigh have a new SOC.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ADXS News